Aclaris Therapeutics, INC. (ACRS) — SEC Filings

Overview

Aclaris Therapeutics, INC. (ACRS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Aclaris Therapeutics, Inc. (ACRS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $45.1 million, up from $35.5 million in the prior year, representing a 27.0% increase. Total revenue declined by 31.3% to $6.5 million for the nine months ended Septem

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 3 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Aclaris Therapeutics, INC. is neutral.

Filing Type Overview

Aclaris Therapeutics, INC. (ACRS) has filed 1 ARS, 1 DEFA14A, 6 10-Q, 10 8-K, 2 DEF 14A, 2 10-K, 5 SC 13G, 11 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

• ARS Filing — ARS · Apr 23, 2026
• DEFA14A Filing — DEFA14A · Apr 23, 2026
• Aclaris' Net Loss Widens 27% Amid Soaring R&D Costs — 10-Q · Nov 6, 2025 Risk: high
  Aclaris Therapeutics, Inc. (ACRS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $45.1 million, up from $35.
• Aclaris Therapeutics Files 8-K — 8-K · Oct 14, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing does not
• Aclaris' Q2 Loss Widens to $24.7M Amid R&D Pipeline Focus — 10-Q · Aug 7, 2025 Risk: high
  Aclaris Therapeutics, Inc. reported a net loss of $24.7 million for the quarter ended June 30, 2025, a significant increase from the net loss of $19.9 million i
• Aclaris Therapeutics Files 8-K — 8-K · Jul 29, 2025 Risk: low
  On July 29, 2025, Aclaris Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements
• Aclaris Therapeutics Files 8-K — 8-K · Jun 30, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on June 30, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing do
• Aclaris Therapeutics Files 8-K with Corporate Governance Updates — 8-K · Jun 5, 2025 Risk: medium
  Aclaris Therapeutics, Inc. filed an 8-K on June 5, 2025, reporting on several key events. These include the departure of directors or certain officers, the elec
• Aclaris Therapeutics Q1 2025 10-Q Filing — 10-Q · May 8, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in Delaware and headquartered in Wayne, PA
• Aclaris Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · Apr 24, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed a DEF 14A on April 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board
• Aclaris Therapeutics Files 2024 Annual Report — 10-K · Feb 27, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, based in Wayne, PA, operates in the pharmaceutical preparat
• Aclaris Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on Regulation FD disclosures and financial statements. The filing does not contain specif
• SC 13G Filing — SC 13G · Nov 25, 2024
• SC 13G Filing — SC 13G · Nov 22, 2024
• SC 13G Filing — SC 13G · Nov 21, 2024
• Aclaris Therapeutics Files 8-K on Agreements & Officer Changes — 8-K · Nov 18, 2024 Risk: medium
  Aclaris Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting on several key events. These include entering into a material definitive agreement, unre
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Aclaris Therapeutics Reports Net Liability — 10-Q · Nov 6, 2024 Risk: high
  Aclaris Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $70.9 million and total liabilities of
• SC 13G/A Filing — SC 13G/A · Oct 9, 2024
• Aclaris Therapeutics Reports Q2 2024 Financials — 10-Q · Aug 7, 2024 Risk: medium
  Aclaris Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $70.9 million and total liabilities of $71.3
• Aclaris Therapeutics Files 8-K — 8-K · Jul 16, 2024 Risk: medium
  On July 16, 2024, Aclaris Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial State
• SC 13G/A Filing — SC 13G/A · Jul 8, 2024
• Aclaris Therapeutics Files 8-K on Shareholder Vote — 8-K · Jun 7, 2024 Risk: low
  Aclaris Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on a matter submitted to a vote of its security holders on June 6, 2024. The filing details t
• Aclaris Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk:
  Aclaris Therapeutics, Inc. (ACRS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Aclaris Therapeutics reported total assets of $70.9 million as of
• Aclaris Therapeutics, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 25, 2024 Risk: low
  Aclaris Therapeutics, Inc. (ACRS) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Aclaris Therapeutics, Inc. filed a Definitive Proxy Statemen
• Aclaris Therapeutics Announces Board and Executive Changes — 8-K · Mar 19, 2024 Risk: low
  Aclaris Therapeutics, Inc. announced on March 14, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Karen L. Smith was appoi
• Aclaris Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  Aclaris Therapeutics, Inc. (ACRS) filed a Annual Report (10-K) with the SEC on February 27, 2024. Aclaris Therapeutics, Inc. filed its 2023 Form 10-K on Februar
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BML Investment Partners Amends Aclaris Therapeutics Stake — SC 13G/A · Feb 8, 2024 Risk: medium
  BML Investment Partners, L.P. has filed an amendment to their Schedule 13G, indicating a change in their beneficial ownership of Aclaris Therapeutics, Inc. comm
• Aclaris Amends 8-K on Executive Changes, Compensation — 8-K/A · Feb 5, 2024
  Aclaris Therapeutics, Inc. filed an 8-K/A on February 5, 2024, amending its previous report from January 15, 2024. This amendment clarifies information regardin
• Millennium Management Updates Aclaris Therapeutics Stake — SC 13G/A · Feb 1, 2024
  Millennium Management LLC, a hedge fund, filed an amended SC 13G/A on February 1, 2024, disclosing its ownership of Aclaris Therapeutics, Inc. common stock as o
• BlackRock Amends Aclaris Therapeutics Stake, Remains Passive Investor — SC 13G/A · Jan 25, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in Aclaris Therapeutics, Inc. as of December 31, 2023. This filing, an am
• Aclaris Therapeutics Files 8-K on Operations, Officer Changes — 8-K · Jan 19, 2024
  Aclaris Therapeutics, Inc. filed an 8-K on January 19, 2024, reporting events that occurred on January 15, 2024. This filing indicates that the company is repor
• BML Investment Partners Discloses New Stake in Aclaris Therapeutics — SC 13G · Jan 16, 2024
  BML Investment Partners, L.P. has disclosed a new significant stake in Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a pharmaceutical company, as of January 11, 20

Risk Profile

Risk Assessment: Of ACRS's 19 recent filings, 3 were flagged as high-risk, 6 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Aclaris Therapeutics, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $6.53M
• Net Income: -$45.13M
• EPS: N/A
• Debt-to-Equity: 0.46
• Cash Position: $167.2M
• Operating Margin: N/A
• Total Assets: $175.53M
• Total Debt: $55.43M

Key Executives

• Wayne, PA
• Dr. Walker
• Dr. Manion
• Mr. Balthaser
• Dr. Karen L. Smith
• Dr. Patrick A. Flaherty

Industry Context

Aclaris Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on the development of novel drug candidates. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and the ability to secure funding to advance pipeline assets.

Top Tags

institutional-ownership (4) · amendment (4) · officer-changes (3) · 10-Q (3) · Biotechnology (2) · Net Loss (2) · Cash Burn (2) · Pharmaceuticals (2) · disclosure (2) · sec-filing (2)

Key Numbers

• Net Loss: $45.1M — Increased from $35.5M for the nine months ended September 30, 2024
• Total Revenue: $6.5M — Decreased from $9.5M for the nine months ended September 30, 2024
• Research and Development Expenses: $36.1M — Increased from $24.6M for the nine months ended September 30, 2024
• Cash, Cash Equivalents and Marketable Securities: $167.2M — As of September 30, 2025
• Accumulated Deficit: $948.0M — As of September 30, 2025
• Increase in Net Loss: 27.0% — Year-over-year increase for the nine months ended September 30, 2025
• Decrease in Total Revenue: 31.3% — Year-over-year decrease for the nine months ended September 30, 2025
• Increase in R&D Expenses: 46.8% — Year-over-year increase for the nine months ended September 30, 2025
• Net Cash Used in Operating Activities: $33.98M — For the nine months ended September 30, 2025, up from $11.14M in 2024
• Outstanding Common Shares: 108,345,239 — As of October 31, 2025
• R&D Expenses: $17.5M — Decreased from $20.1M in Q2 2024, reflecting a strategic shift in pipeline investment.
• Cash and Equivalents: $105.3M — Down from $120.5M at year-end 2024, indicating ongoing cash burn.
• Period End Date: June 30, 2025 — The reporting period for the financial results.
• Reporting Period: Q1 2025 — First quarter of fiscal year 2025
• As of Date: March 31, 2025 — End date for financial reporting

Forward-Looking Statements

• {"claim":"BML Investment Partners, L.P. has likely reduced its stake in Aclaris Therapeutics, Inc. below the 5% threshold, or changed its investment intent, leading to this amendment.","entity":"BML Investment Partners, L.P.","targetDate":"N/A","confidence":"high"}

Frequently Asked Questions